220 related articles for article (PubMed ID: 28893210)
21. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma.
Yang Q; Bariani MV; Falahati A; Khosh A; Lastra RR; Siblini H; Boyer TG; Al-Hendy A
Cells; 2022 Jul; 11(14):. PubMed ID: 35883603
[TBL] [Abstract][Full Text] [Related]
22. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
23. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Ingham M; Allred JB; Chen L; Das B; Kochupurakkal B; Gano K; George S; Attia S; Burgess MA; Seetharam M; Boikos SA; Bui N; Chen JL; Close JL; Cote GM; Thaker PH; Ivy SP; Bose S; D'Andrea A; Marino-Enriquez A; Shapiro GI; Schwartz GK
J Clin Oncol; 2023 Sep; 41(25):4154-4163. PubMed ID: 37467452
[TBL] [Abstract][Full Text] [Related]
24. Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma.
Abedin Y; Gabrilovich S; Alpert E; Rego E; Begum S; Zhao Q; Heller D; Einstein MH; Douglas NC
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682660
[TBL] [Abstract][Full Text] [Related]
25. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
26. Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
Wang X; Li C; Lou L; Zhu H
Anticancer Res; 2024 Apr; 44(4):1465-1473. PubMed ID: 38537953
[TBL] [Abstract][Full Text] [Related]
27. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
28. Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.
Arend RC; Toboni MD; Montgomery AM; Burger RA; Olawaiye AB; Monk BJ; Herzog TJ
Oncologist; 2018 Dec; 23(12):1533-1545. PubMed ID: 30139839
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of miR‑10b‑5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing‑based approach.
Yoshida K; Yokoi A; Kitagawa M; Sugiyama M; Yamamoto T; Nakayama J; Yoshida H; Kato T; Kajiyama H; Yamamoto Y
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36929268
[TBL] [Abstract][Full Text] [Related]
30. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
31. FGFR4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma.
Zhang P; Zhang H; Wang Y
Cell Tissue Res; 2021 Feb; 383(2):865-879. PubMed ID: 33151453
[TBL] [Abstract][Full Text] [Related]
32. Perivascular Epithelioid Cell Tumors (PEComas) and Smooth Muscle Tumors of the Uterus.
Fadare O
Am J Surg Pathol; 2007 Sep; 31(9):1454-5; author reply 1455-6. PubMed ID: 17721205
[No Abstract] [Full Text] [Related]
33. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
Brewer Savannah KJ; Demicco EG; Lusby K; Ghadimi MP; Belousov R; Young E; Zhang Y; Huang KL; Lazar AJ; Hunt KK; Pollock RE; Creighton CJ; Anderson ML; Lev D
Clin Cancer Res; 2012 Sep; 18(17):4633-45. PubMed ID: 22821997
[TBL] [Abstract][Full Text] [Related]
34. Integrated mutational landscape analysis of uterine leiomyosarcomas.
Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
[TBL] [Abstract][Full Text] [Related]
35. Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.
Lange SE; Liu J; Adkins DR; Powell MA; Van Tine BA; Mutch DG
Gynecol Oncol; 2016 Feb; 140(2):307-12. PubMed ID: 26718726
[TBL] [Abstract][Full Text] [Related]
36. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
38. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis.
Ijaz I; Shahzad MN; Hosseinifard H; Liu S; Sefidan MO; Kahloon LE; Imani S; Hua Z; Zhang YQ
Cancer Med; 2023 Jul; 12(13):13894-13911. PubMed ID: 37081717
[TBL] [Abstract][Full Text] [Related]
40. [The loss of heterozygosity and microsatellite instability analysis in differential diagnostics of leiomyosarcoma and proliferative leiomyoma of the uterus].
Shikeeva AA; Kekeeva TV; Zavalishina LÉ; Andreeva IuIu; Frank GA
Arkh Patol; 2011; 73(4):47-50. PubMed ID: 22164433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
